Trial Profile
A Phase 2, Open-label, Randomized, Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2023
Price :
$35
*
At a glance
- Drugs Inarigivir soproxil (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACHIEVE
- Sponsors F-star Therapeutics; Spring Bank Pharmaceuticals
- 01 Jan 2023 Results published in the Liver International
- 17 Oct 2019 Status changed from active, no longer recruiting to completed, according to a Spring Bank Pharmaceuticals media release.
- 29 Apr 2019 According to a Spring Bank Pharmaceuticals media release, the company expects to announce initial results from an exploratory cohort of NUC-suppressed chronic HBV patients at a major scientific conference in the second half of 2019.